Clinical trial
Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With…
NCT00096395 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00096395 |
|---|---|
| Title | Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer |
| Official title | A Phase 2 Study of BAY 43-9006 in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer |
| Intervention type | Drug, Other |
| Interventions | gemcitabine hydrochloride, sorafenib tosylate, laboratory biomarker analysis |
| Enrollment | 33 |
| Start date | Sep 1, 2004 |
| Primary completion | Feb 1, 2007 |
| First posted | Nov 9, 2004 |
| Last update posted | Jun 13, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: